Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Durgeau, Aurélie ^a,b   Virk, Yasemin ^a   Corgnac, Stéphanie ^a   Mami Chouaib, Fathia ^a  

^a Faculty of Medicine University of Paris Sud   (France)

^b ElyssaMed   (France)

Author keywords

Cytotoxic T lymphocytes; Immunotherapy of cancer; Neoantigens; T cell receptor repertoire; Tumor antigens

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD8 ANTIGEN; EPITOPE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; MALIGNANT NEOPLASM; REVIEW; TARGET CELL; TUMOR IMMUNITY;

EID: 85040984776     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00014     Document Type: Review

References (196)

1. Bossi G, Trambas C, Booth S, Clark R, Stinchcombe J, Griffiths GM. The secretory synapse: the secrets of a serial killer. Immunol Rev (2002) 189:152-60. doi:10.1034/j.1600-065X.2002.18913.x
2. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005) 102(18):6437-42. doi:10.1073/pnas.0502467102
3. Le Floc'h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, Bismuth G, et al. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 204(3):559-70. doi:10.1084/jem.20061524
4. Eichler W, Ruschpler P, Wobus M, Drossler K. Differentially induced expression of C-type lectins in activated lymphocytes. J Cell Biochem Suppl (2001) Suppl 36:201-8. doi:10.1002/jcb.1107
5. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol (2007) 7(9):737-44. doi:10.1038/nri2144
6. Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, et al. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res (2007) 13(24):7459-68. doi:10.1158/1078-0432.CCR-07-1166
7. Wang E, Selleri S, Marincola FM. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clin Cancer Res (2007) 13(24):7228-31. doi:10.1158/1078-0432.CCR-07-2150
8. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev (2001) 181:158-69. doi:10.1034/j.1600-065X.2001.1810113.x
9. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 14(2):123-33. doi:10.1016/S1074-7613(01)00095-4
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 19:197-223. doi:10.1146/annurev.immunol.19.1.197
11. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 96(12):6879-84. doi:10.1073/pnas.96.12.6879
12. Davis SJ, Ikemizu S, Evans EJ, Fugger L, Bakker TR, van der Merwe PA. The nature of molecular recognition by T cells. Nat Immunol (2003) 4(3):217-24. doi:10.1038/ni0303-217
13. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3(6):682-5. doi:10.1038/nm0697-682
14. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 4(6):420-31. doi:10.1038/nri1371
15. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 9(4):271-85. doi:10.1038/nri2526
16. Ye Q, Song DG, Powell DJ Jr. Finding a needle in a haystack: activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients. Oncoimmunology (2013) 2(12):e27184. doi:10.4161/onci.27184
17. Adler AJ, Vella AT. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 2(1):e22837. doi:10.4161/onci.22837
18. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today (1997) 18(6):267-8. doi:10.1016/S0167-5699(97)80020-5
19. Echchakir H, Vergnon I, Dorothee G, Grunenwald D, Chouaib S, Mami-Chouaib F. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol (2000) 12(4):537-46. doi:10.1093/intimm/12.4.537
20. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001) 61(9):3718-24
21. SlingluffCL Jr, Cox AL, Stover JM Jr, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res (1994) 54(10):2731-7
22. Weynants P, Thonnard J, Marchand M, Delos M, Boon T, Coulie PG. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med (1999) 159(1):55-62. doi:10.1164/ajrccm.159.1.9805073
23. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 353(25):2654-66. doi:10.1056/NEJMoa051424
24. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother (2006) 29(3):233-40. doi:10.1097/01.cji.0000199193.29048.56
25. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 167(3):1137-40. doi:10.4049/jimmunol.167.3.1137
26. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and-non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol (2011) 32(9):428-33. doi:10.1016/j.it.2011.06.002
27. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506
28. Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, et al. Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T-cells, which dampen CD8+ T-cell antitumor reactivity. Cancer Res (2015) 75(18):3747-59. doi:10.1158/0008-5472.CAN-14-2956
29. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 10(5):588-94. doi:10.1016/S0952-7915(98)80228-8
30. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998) 188(12):2199-204. doi:10.1084/jem.188.12.2199
31. Ahrends T, Spanjaard A, Pilzecker B, Babala N, Bovens A, Xiao Y, et al. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity (2017) 47(5):848-61.e5. doi:10.1016/j.immuni.2017.10.009
32. Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R. Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol (2010) 29(4):371-402. doi:10.3109/08830185.2010.489658
33. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 520(7549):692-6. doi:10.1038/nature14426
34. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2015) 21(1):81-5. doi:10.1038/nm.3773
35. Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M, et al. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and-mediated cytotoxicity. J Immunol (2002) 169(2):809-17. doi:10.4049/jimmunol.169.2.809
36. Echchakir H, Bagot M, Dorothee G, Martinvalet D, Le Gouvello S, Boumsell L, et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol (2000) 115(1):74-80. doi:10.1046/j.1523-1747.2000.00995.x
37. Darrow TL, Abdel-Wahab Z, Quinn-Allen MA, Seigler HF. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8-T-cell clone restricted by HLA-A2. Cell Immunol (1996) 172(1):52-9. doi:10.1006/cimm.1996.0214
38. Zennadi R, Abdel-Wahab Z, Seigler HF, Darrow TL. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol (2001) 210(2):96-105. doi:10.1006/cimm.2001.1809
39. Huarte E, Karbach J, Gnjatic S, Bender A, Jager D, Arand M, et al. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25-CD8-T cell clones. Cancer Immun (2004) 4:15
40. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 358(25):2698-703. doi:10.1056/NEJMoa0800251
41. Yasukawa M, Ohminami H, Yakushijin Y, Arai J, Hasegawa A, Ishida Y, et al. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. J Immunol (1999) 162(10):6100-6
42. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 168(11):5954-8. doi:10.4049/jimmunol.168.11.5954
43. Nagata S, Golstein P. The Fas death factor. Science (1995) 267(5203):1449-56. doi:10.1126/science.7533326
44. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-7. doi:10.1126/science.1840703
45. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54(3):187-207. doi:10.1007/s00262-004-0560-6
46. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 14(2):135-46. doi:10.1038/nrc3670
47. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (2015) 348(6230):69-74. doi:10.1126/science.aaa4971
48. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 371(23):2189-99. doi:10.1056/NEJMoa1406498
49. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 348(6230):124-8. doi:10.1126/science.aaa1348
50. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 351(6280):1463-9. doi:10.1126/science.aaf1490
51. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 344(6184):641-5. doi:10.1126/science.1251102
52. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 20(13):3401-10. doi:10.1158/1078-0432.CCR-14-0433
53. Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science (2017) 356(6334):200-5. doi:10.1126/science.aak9510
54. Pritchard AL, Burel JG, Neller MA, Hayward NK, Lopez JA, Fatho M, et al. Exome sequencing to predict neoantigens in melanoma. Cancer Immunol Res (2015) 3(9):992-8. doi:10.1158/2326-6066.CIR-15-0088
55. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 348(6236):803-8. doi:10.1126/science.aaa3828
56. Gueguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol (1998) 160(12):6188-94
57. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med (1997) 186(5):785-93. doi:10.1084/jem.186.5.785
58. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 183(3):1185-92. doi:10.1084/jem.183.3.1185
59. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269(5228):1281-4. doi:10.1126/science.7652577
60. Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004) 172(10):6057-64. doi:10.4049/jimmunol.172.10.6057
61. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 71(4):1253-62. doi:10.1158/0008-5472.CAN-10-2693
62. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 102(44):16013-8. doi:10.1073/pnas.0500090102
63. Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E, et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol (2001) 166(4):2871-7. doi:10.4049/jimmunol.166.4.2871
64. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 92(17):7976-80. doi:10.1073/pnas.92.17.7976
65. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res (1999) 59(22):5785-92
66. Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol (2000) 164(11):6057-66. doi:10.4049/jimmunol.164.11.6057
67. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol (1999) 29(2):592-601. doi:10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2
68. Linard B, Bezieau S, Benlalam H, Labarriere N, Guilloux Y, Diez E, et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol (2002) 168(9):4802-8. doi:10.4049/jimmunol.168.9.4802
69. Vigneron N, Ooms A, Morel S, Degiovanni G, Van Den Eynde BJ. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun (2002) 2:9
70. Hogan KT, Eisinger DP, Cupp SB III, Lekstrom KJ, Deacon DD, Shabanowitz J, et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res (1998) 58(22):5144-50
71. Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer (2006) 118(8):1992-7. doi:10.1002/ijc.21594
72. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res (2001) 61(10):4078-83
73. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med (1996) 183(6):2501-8. doi:10.1084/jem.183.6.2501
74. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol (1999) 162(3):1730-8
75. Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res (2003) 63(20):6735-43
76. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol (2005) 174(5):2661-70. doi:10.4049/jimmunol.174.5.2661
77. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 284(5418):1351-4. doi:10.1126/science.284.5418.1351
78. Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002) 195(11):1397-406. doi:10.1084/jem.20020141
79. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med (1999) 189(10):1659-68. doi:10.1084/jem.189.10.1659
80. Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res (2002) 62(19):5505-9
81. Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, et al. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol (2003) 170(12):6363-70. doi:10.4049/jimmunol.170.12.6363
82. Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 189(5):757-66. doi:10.1084/jem.189.5.757
83. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016) 22(4):433-8. doi:10.1038/nm.4051
84. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547(7662):222-6. doi:10.1038/nature23003
85. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19(6):747-52. doi:10.1038/nm.3161
86. Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res (2014) 20(5):1125-34. doi:10.1158/1078-0432.CCR-13-2147
87. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol (1999) 17:739-79. doi:10.1146/annurev.immunol.17.1.739
88. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity (2007) 26(4):397-406. doi:10.1016/j.immuni.2007.04.003
89. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 74:181-273. doi:10.1016/S0065-2776(08)60911-6
90. Kessler JH, Khan S, Seifert U, Le Gall S, Chow KM, Paschen A, et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2011) 12(1):45-53. doi:10.1038/ni.1974
91. Parmentier N, Stroobant V, Colau D, de Diesbach P, Morel S, Chapiro J, et al. Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol (2010) 11(5):449-54. doi:10.1038/ni.1862
92. Medina F, Ramos M, Iborra S, de Leon P, Rodriguez-Castro M, Del Val M. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo. J Immunol (2009) 183(7):4639-47. doi:10.4049/jimmunol.0901356
93. Van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, Roseboom M, et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 12(4):417-24. doi:10.1038/nm1381
94. El Hage F, Stroobant V, Vergnon I, Baurain JF, Echchakir H, Lazar V, et al. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A (2008) 105(29):10119-24. doi:10.1073/pnas.0802753105
95. Durgeau A, El Hage F, Vergnon I, Validire P, de Montpreville V, Besse B, et al. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol (2011) 187(11):5532-9. doi:10.4049/jimmunol.1102060
96. Ngoenkam J, Schamel WW, Pongcharoen S. Selected signalling proteins recruited to the T-cell receptor-CD3 complex. Immunology (2017) 153(1):42-50. doi:10.1111/imm.12809
97. Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. VDJ recombination. Immunol Today (1992) 13(8):306-14. doi:10.1016/0167-5699(92)90043-7
98. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature (1988) 334(6181):395-402. doi:10.1038/334395a0
99. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A (1993) 90(9):4319-23. doi:10.1073/pnas.90.9.4319
100. Gorski J, Yassai M, Zhu X, Kissela B, Kissella B, Keever C, et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol (1994) 152(10):5109-19
101. Xin-Sheng Y, Zheng-Jun X, Li M, Wan-Bang S, Wei-Yang Z, Qian W, et al. Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia. Clin Lab Haematol (2006) 28(6):405-15. doi:10.1111/j.1365-2257.2006.00827.x
102. Wang CY, Fang YX, Chen GH, Jia HJ, Zeng S, He XB, et al. Analysis of the CDR3 length repertoire and the diversity of T cell receptor alpha and beta chains in swine CD4+ and CD8+ T lymphocytes. Mol Med Rep (2017) 16(1):75-86. doi:10.3892/mmr.2016.5981
103. Ria F, van den Elzen P, Madakamutil LT, Miller JE, Maverakis E, Sercarz EE. Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. Curr Mol Med (2001) 1(3):297-304. doi:10.2174/1566524013363690
104. Even J, Lim A, Puisieux I, Ferradini L, Dietrich PY, Toubert A, et al. T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. Res Immunol (1995) 146(2):65-80. doi:10.1016/0923-2494(96)80240-9
105. Gaudin C, Dietrich PY, Robache S, Guillard M, Escudier B, Lacombe MJ, et al. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res (1995) 55(3):685-90
106. Valteau D, Scott V, Carcelain G, Hartmann O, Escudier B, Hercend T, et al. T-cell receptor repertoire in neuroblastoma patients. Cancer Res (1996) 56(2):362-9
107. Echchakir H, Asselin-Paturel C, Dorothee G, Vergnon I, Grunenwald D, Chouaib S, et al. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int J Cancer (1999) 81(2):205-13. doi:10.1002/(SICI)1097-0215(19990412)81:2<205::AID-IJC7>3.0.CO;2-M
108. Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami-Chouaib F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci U S A (2002) 99(14):9358-63. doi:10.1073/pnas.142308199
109. Ingen-Housz-Oro S, Bussel A, Flageul B, Michel L, Dubertret L, Kourilsky P, et al. A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood (2002) 100(6):2168-74
110. Lim A, Baron V, Ferradini L, Bonneville M, Kourilsky P, Pannetier C. Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. J Immunol Methods (2002) 261(1-2):177-94. doi:10.1016/S0022-1759(02)00004-2
111. Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res (2008) 18(6):839-46. doi:10.1101/gr.073262.107
112. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol (2008) 26(10):1135-45. doi:10.1038/nbt1486
113. Woodsworth DJ, Castellarin M, Holt RA. Sequence analysis of T-cell repertoires in health and disease. Genome Med (2013) 5(10):98. doi:10.1186/gm502
114. Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res (2009) 19(10):1817-24. doi:10.1101/gr.092924.109
115. Boria I, Cotella D, Dianzani I, Santoro C, Sblattero D. Primer sets for cloning the human repertoire of T cell receptor variable regions. BMC Immunol (2008) 9:50. doi:10.1186/1471-2172-9-50
116. Warren RL, Nelson BH, Holt RA. Profiling model T-cell metagenomes with short reads. Bioinformatics (2009) 25(4):458-64. doi:10.1093/bioinformatics/btp010
117. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 19(11):1534-41. doi:10.1038/nm.3359
118. Brown SD, Raeburn LA, Holt RA. Profiling tissue-resident T cell repertoires by RNA sequencing. Genome Med (2015) 7:125. doi:10.1186/s13073-015-0248-x
119. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet (2016) 48(7):725-32. doi:10.1038/ng.3581
120. Fang H, Yamaguchi R, Liu X, Daigo Y, Yew PY, Tanikawa C, et al. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor alpha and beta chains using next-generation sequencing (NGS). Oncoimmunology (2014) 3(12):e968467. doi:10.4161/21624011.2014.968467
121. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, et al. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov (2017) 7(10):1088-97. doi:10.1158/2159-8290.CD-17-0256
122. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 6(238):238ra70. doi:10.1126/scitranslmed.3008211
123. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med (2017) 9(379):eaah3560. doi:10.1126/scitranslmed.aah3560
124. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515(7528):568-71. doi:10.1038/nature13954
125. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466
126. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 350(6257):207-11. doi:10.1126/science.aad0095
127. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372(26):2521-32. doi:10.1056/NEJMoa1503093
128. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690
129. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387(10027):1540-50. doi:10.1016/S0140-6736(15)01281-7
130. Humphries C. Adoptive cell therapy: honing that killer instinct. Nature (2013) 504(7480):S13-5. doi:10.1038/504S13a
131. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 32:189-225. doi:10.1146/annurev-immunol-032713-120136
132. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature (2017) 547(7662):217-21. doi:10.1038/nature22991
133. Lerret NM, Marzo AL. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology (2013) 2(2):e22731. doi:10.4161/onci.22731
134. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 26(4):332-42. doi:10.1097/00002371-200307000-00005
135. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-4. doi:10.1126/science.1076514
136. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17(13):4550-7. doi:10.1158/1078-0432.CCR-11-0116
137. Chandran SS, Somerville RPT, Yang JC, Sherry RM, KlebanoffCA, GoffSL, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol (2017) 18(6):792-802. doi:10.1016/S1470-2045(17)30251-6
138. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 257(1):56-71. doi:10.1111/imr.12132
139. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 31(17):2152-9. doi:10.1200/JCO.2012.46.6441
140. Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, et al. Tumor-and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol Res (2016) 4(9):734-43. doi:10.1158/2326-6066.CIR-16-0001
141. Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res (2017) 23(10):2491-505. doi:10.1158/1078-0432.CCR-16-2680
142. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 536(7614):91-5. doi:10.1038/nature18945
143. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest (2011) 121(6):2350-60. doi:10.1172/JCI46102
144. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol (2015) 194(7):3475-86. doi:10.4049/jimmunol.1402711
145. Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol (2017) 28(suppl_12):xii18-32. doi:10.1093/annonc/mdx238
146. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol (2013) 4:371. doi:10.3389/fimmu.2013.00371
147. June CH. Remote controlled CARs: towards a safer therapy for leukemia. Cancer Immunol Res (2016) 4(8):643. doi:10.1158/2326-6066.CIR-16-0132
148. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens (2009) 74(4):277-89. doi:10.1111/j.1399-0039.2009.01336.x
149. Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br J Haematol (2016) 172(5):685-98. doi:10.1111/bjh.13889
150. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol (2011) 8(10):577-85. doi:10.1038/nrclinonc.2011.116
151. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol (2010) 136(3):338-47. doi:10.1016/j.clim.2010.04.013
152. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3(1):35-45. doi:10.1038/nrc971
153. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29(7):917-24. doi:10.1200/JCO.2010.32.2537
154. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 287(27):23068-78. doi:10.1074/jbc. M112.357673
155. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-9. doi:10.1126/science.1129003
156. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 114(3):535-46. doi:10.1182/blood-2009-03-211714
157. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 10(5):267-76. doi:10.1038/nrclinonc.2013.46
158. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 118(18):4817-28. doi:10.1182/blood-2011-04-348540
159. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 3(95):95ra73. doi:10.1126/scitranslmed.3002842
160. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5(177):177ra38. doi:10.1126/scitranslmed.3005930
161. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 371(16):1507-17. doi:10.1056/NEJMoa1407222
162. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2015) 385(9967):517-28. doi:10.1016/S0140-6736(14)61403-3
163. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2(2):112-20. doi:10.1158/2326-6066.CIR-13-0170
164. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi:10.1038/nrc3239
165. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 348(6230):56-61. doi:10.1126/science.aaa8172
166. Topalian SL, Wolchok JD, Chan TA, Mellman I, Palucka K, Banchereau J, et al. Immunotherapy: the path to win the war on cancer? Cell (2015) 161(2):185-6. doi:10.1016/j.cell.2015.03.045
167. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature (2016) 537(7620):417-21. doi:10.1038/nature19330
168. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12(6):492-9. doi:10.1038/ni.2035
169. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med (2015) 373(1):23-34. doi:10.1056/NEJMoa1504030
170. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 207(10):2187-94. doi:10.1084/jem.20100643
171. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 19(5):997-1008. doi:10.1158/1078-0432.CCR-12-2214
172. Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res (2015) 21(5):1127-38. doi:10.1158/1078-0432.CCR-14-1339
173. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med (2014) 6(254):254ra128. doi:10.1126/scitranslmed.3008918
174. Luksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature (2017) 551(7681):517-20. doi:10.1038/nature24473
175. Gilboa E. The makings of a tumor rejection antigen. Immunity (1999) 11(3):263-70. doi:10.1016/S1074-7613(00)80101-6
176. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med (2016) 375(9):819-29. doi:10.1056/NEJMoa1604958
177. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov (2017) 7(2):188-201. doi:10.1158/2159-8290.CD-16-1223
178. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell (2016) 167(2):397-404.e9. doi:10.1016/j.cell.2016.08.069
179. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12(4):265-77. doi:10.1038/nrc3258
180. Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res (2017) 5(5):347-54. doi:10.1158/2326-6066.CIR-17-0112
181. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 94(11):805-18. doi:10.1093/jnci/94.11.805
182. Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med (2013) 15(82):166-76
183. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol (2006) 24:175-208. doi:10.1146/annurev.immunol.24.021605.090733
184. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4(3):321-7. doi:10.1038/nm0398-321
185. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 105(10):3849-54. doi:10.1073/pnas.0800080105
186. Quakkelaar ED, Melief CJ. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol (2012) 114:77-106. doi:10.1016/B978-0-12-396548-6.00004-4
187. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest (2015) 125(9):3401-12. doi:10.1172/JCI80009
188. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 10(9):909-15. doi:10.1038/nm1100
189. KlebanoffCA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 239(1):27-44. doi:10.1111/j.1600-065X.2010.00979.x
190. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res (2015) 21(5):1019-27. doi:10.1158/1078-0432.CCR-14-2708
191. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 16(4):219-33. doi:10.1038/nrc.2016.16
192. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J (2013) 32(2):194-203. doi:10.1038/emboj.2012.333
193. Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 18(3):255-62. doi:10.1038/ni.3682
194. Oliveira CC, Querido B, Sluijter M, de Groot AF, van der Zee R, Rabelink MJ, et al. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol (2013) 191(8):4020-8. doi:10.4049/jimmunol.1301496
195. Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, et al. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest (2016) 126(2):784-94. doi:10.1172/JCI83671
196. Butterfield LH. Cancer vaccines. BMJ (2015) 350:h988. doi:10.1136/bmj.h988